F8 and hemophilia A: An international, prospective, randomized-controlled clinical trial in previously untreated patients with hemophilia A reported significant reductions in the cumulative incidence of inhibitors, including high-titer inhibitors, in children on FVIII prophylaxis with plasma-derived VWF-containing FVIII concentrates compared to recombinant FVIII products without VWF (76).